Galera Therapeutics Common Stock Net 2018-2024 | GRTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Galera Therapeutics common stock net from 2018 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Galera Therapeutics common stock net from 2018 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$139.4B
Bristol Myers Squibb (BMY)	$115.2B
Gilead Sciences (GILD)	$114.5B
Vertex Pharmaceuticals (VRTX)	$104.5B
CSL (CSLLY)	$84.4B
Regeneron Pharmaceuticals (REGN)	$78.6B
GSK (GSK)	$70.4B
Argenex SE (ARGX)	$37.4B
Alnylam Pharmaceuticals (ALNY)	$30.1B
BioNTech SE (BNTX)	$27.6B
Biogen (BIIB)	$21.9B
Illumina (ILMN)	$20.8B
BeiGene (ONC)	$18B
Moderna (MRNA)	$16.2B
Genmab (GMAB)	$13.9B
Incyte (INCY)	$13.4B
BioMarin Pharmaceutical (BMRN)	$12.7B
Insmed (INSM)	$12.5B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.4B
Exact Sciences (EXAS)	$10.5B
Vaxcyte (PCVX)	$10.4B
QIAGEN (QGEN)	$10.2B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.9B
Roivant Sciences (ROIV)	$8.8B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8B